A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...
The MarketWatch News Department was not involved in the creation of this content. IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its ...
IsoPSA clinically validated in a study of over 1000 patients and demonstrates significant clinical utility in a study of 900 patients in a real-world setting CLEVELAND--(BUSINESS WIRE)--Cleveland ...
A multi-center study that validates the clinical performance of IsoPSA - a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard ...
One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility. The ...
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA ...
Using the prostate-specific antigen test to screen for prostate cancer is controversial: First, doctors used to perform it on nearly every man over 50. Then in 2012, the U.S. Preventive Task Force ...
A PSA or test prostate-specific antigen test after 50 years of age is usually advised to men to check on the status of their prostate gland. An elevated level of PSA in the blood is seen as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback